Senseonics Shows Year-Long Eversense 365 Maintains Accuracy and High Adherence

The findings point to fewer clinic visits for sensor replacement, which could reduce interruptions to daily glucose monitoring.

Overview

Senseonics presented expanded company-reported real-world data at the American Diabetes Association showing sustained performance for its Eversense 365 implantable CGM over a single 365-day sensor lifetime.
The analysis covered 12,360 open-loop sensors and 153 sensors used with the twiist automated insulin delivery system, with the company reporting overall mean GMI of 7.16% and mean Time In Range of 66.16%.
Average transmitter wear time across the full dataset was 93.19%, and more than 81% of users met the report's hypoglycemia targets, with similar adherence and glycemic outcomes in the first and second six-month periods.
Early results for the twiist closed-loop pairing showed stronger short-term control (mean TIR ≈76.08%, GMI 6.78% after 30 days) and very high median sensor wear time of 99.46%, but the closed-loop sample is small and preliminary.
Eversense 365 is the only implantable CGM cleared for up to 365 days and requires clinician insertion and removal; Senseonics' company analyses compare favorably to published real-world ranges but larger and peer-reviewed studies are needed to confirm clinical benefits and AID advantages.